The U.S. FDA cleared Takeda’s hepcidin mimetic Mimrylo (rusfertide) for treatment of erythrocytosis in adults with polycythemia vera (PV), using phase 3 data already spotlighted in the drug’s late-stage program. Mimrylo is designed to restore hepcidin-related signaling, which is central to iron regulation. The clearance adds another hepcidin-pathway option for PV patients who need better control of blood counts and iron-related complications. It also sharpens competitive positioning for drugs that modulate iron metabolism in myeloproliferative neoplasms. For clinicians, the approval reduces reliance on off-label approaches for iron and erythrocytosis management. For Takeda, Mimrylo becomes a key near-term growth lever tied to a defined, label-directed patient population.